Elsevier

Toxicology in Vitro

Volume 27, Issue 5, August 2013, Pages 1578-1583
Toxicology in Vitro

Preservation, induction or incorporation of metabolism into the in vitro cellular system − Views to current opportunities and limitations

https://doi.org/10.1016/j.tiv.2012.06.002Get rights and content

Abstract

Metabolism plays a major role in the toxicokinetics of a vast majority of substances, although other dispositional processes have to be considered as well. There are currently a large repertoire of primary or permanent cells/cell lines with variable metabolic capacities and a number of experimental approaches to preserve, induce or incorporate biotransformation enzymes for the development of metabolically competent cells. Many of these cell lines possess also other important dispositional characteristics mimicking the in vivo situation. Such cell models can be employed in studies targeted for estimating metabolic disposition of a substance or the production of active metabolites and ensuing toxic end points. There are also ways to collect metabolic information by using a large number of non-cellular systems and build a coherent view on metabolism, although not really replacing the actual cellular system. Early consideration of metabolic competence is a necessary prerequisite for the validation and use of cellular systems for toxicity studies and in vitro–in vivo extrapolation.

Highlights

► Metabolic capability is needed in in vitro systems for improving in vivo relevance. ► Bioreactors produce metabolites for target exposure. ► Preservation by appropriate culture conditions enhance metabolic competence. ► Incorporation by genomic techniques restore metabolism in otherwise deficient cells. ► Stem cell-derived hepatocytes will guarantee unlimited supply of competent cells.

Introduction

Toxicokinetic (TK) characteristics of chemicals are determined by passive and active factors, and among active factors, metabolism (xenobiotic-metabolizing enzymes) and transport (uptake and efflux transporters) are the most important. The expression and activity of the enzymes and transporters is regulated, for example, by ligand-activated nuclear receptors in the organs of importance for TK. If these processes were to be measured in in vitro cellular systems, it is of utmost importance to ensure that they are actually functional and preferably at the similar level as in vivo (see e.g. Coecke et al., 2006, Adler et al., 2011). Fig. 1 demonstrates the central role of metabolism affecting the concentration of a substance at the active site (receptor) and thus determining to a large extent the eventual toxicodynamic consequences. Thus the preservation, induction and/or incorporation of relevant metabolic capacity are one of the challenges, which have to be solved before truly reliable toxicity testing systems can be achieved.

Section snippets

Why it is important to have metabolism in the cellular system for toxicity testing

From the test system point of view, metabolic competence may become of importance for determining local extra or intracellular concentrations of the studied substance and its active or inactive metabolites. It is obvious that efficient metabolism may decrease the concentration of the substance to the point that no effect could be revealed. On the other hand, lack of metabolism may be detrimental to the performance of the test if metabolic activation is a prerequisite for the effect.

One of the

Toxicologically important organs and activities for metabolism

Critical organs for toxicologically important xenobiotic metabolism and active transporters are the portals to the body (lung, skin, gastrointestinal tract), internal organs for metabolism (liver) and excretion (liver and kidneys) and specialized barriers such as the placenta regulating fetal exposure or blood–brain barrier for CNS drug action and toxicity.

One of the crucial considerations here is the adequacy of the liver as a master organ for metabolism studies. Hepatotoxicity has been one of

Examples of commonly used in vitro systems

Some representative in vitro systems currently in use are presented in Table 1. For comparison, the table starts with some non-cellular systems, which are regularly used especially in drug development. Many of these in vitro non-cell ex vivo systems such as liver microsomes or homogenates rather consistently represent the original tissue and can be used in the initial studies on the characterization and quantitation of metabolic profiles and activities. However, such systems are not suitable as

Preservation, induction and/or incorporation of metabolism into the cellular systems

There are several potential techniques to incorporate metabolism into cellular systems, which are collected into Table 2.

Extra-hepatic tissues and incorporation of metabolism

Xenobiotic metabolism enzymes display tissue specific-expression and regulation (e.g. Baron et al., 2008), which is of importance for several reasons. First of all, cell-specific profile of drug metabolizing enzymes should be studied so that an appropriate in vitro cell model could be sought. Table 3 contains some examples of the expression of drug-metabolizing enzymes in extrahepatic tissues. These data are required as a necessary framework for the development of metabolically competent

How to get the information about metabolism without actual incorporation

Chemically reactive metabolites pose a major challenge especially in drug development, as they have the potential to alter biological function and initiate serious adverse drug reactions. These include hepatotoxicity, skin rashes, agranulocytosis, and aplastic anemia, in drug-treated patients. Pharmaceutical companies employ today several different strategies to evaluate reactive metabolites. At early stages of drug development, molecular modeling (in silico) methods can fairly reliably predict

The integration of in vitro data into human risk assessment

Ultimately, the information derived from in vitro and in silico studies described above has to be used for risk assessment. Thousands of articles have been published on the in vitro metabolism and interactions of particular chemicals using human and animal-derived in vitro models. However, the main challenge is how to translate the in vitro measured characteristics into the information useful for the risk assessment process.

For risk assessment, when only in vitro data is available, a number of

Conclusions

A necessary condition to develop realistic and reliable experimental in vitro systems is their early characterization regarding metabolism and other important kinetic processes (e.g. transporters), because the thorough characterization is the prerequisite for the validation and use of cellular systems for pharmacological and toxicological purposes. There are currently a number of experimental possibilities, although also many limitations, to develop cells capable of metabolism and possessing

Conflict of interest

None declared.

Acknowledgments

Original research of the authors has been support by respective universities and by grants from The Academy of Finland, TEKES State Granting Agency for Research and Innovation, and by intellectual and travel support from EU COST and FW programmes.

References (38)

  • K. Vähäkangas et al.

    Experimental methods to study human transplacental exposure to genotoxic agents

    Mutat. Res.

    (2006)
  • S. Adler et al.

    Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010

    Arch. Toxicol.

    (2011)
  • S. Anthérieu et al.

    Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells

    Drug Metab. Dispos.

    (2010)
  • J.M. Baron et al.

    Expression and function of cytochrome p450-dependent enzymes in human skin cells

    Curr. Med. Chem.

    (2008)
  • Z.E. Barter et al.

    Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver

    Curr. Drug Metab.

    (2007)
  • S. Coecke et al.

    Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54

    Altern. Lab. Anim.

    (2006)
  • M. Darnell et al.

    Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor

    Drug Metab. Dispos.

    (2011)
  • Declèves, X., Jacob, A., Yousif, S., Shawahna, R., Potin, S., Scherrmann, J.M., 2011. Interplay of Drug Metabolizing...
  • M.T. Donato et al.

    Cell lines: a tool for in vitro drug metabolism studies

    Curr. Drug Metab.

    (2008)
  • Cited by (12)

    • Analytical challenges for conducting rapid metabolism characterization for QIVIVE

      2015, Toxicology
      Citation Excerpt :

      However, it is equally clear that a single tool cannot cover completely the huge variability of chemical space, and therefore several techniques for separation and for detection, identification and quantification are needed. Furthermore, it should be stressed that incubation systems and conditions are crucial for creating the necessary preconditions to acquire a toxicologically meaningful outcome (see Pelkonen et al., 2013). Furthermore, one cannot neglect the significance of a proper sample preparation technique.

    • Biotransformation in vitro: An essential consideration in the quantitative in vitro-to-in vivo extrapolation (QIVIVE) of toxicity data

      2015, Toxicology
      Citation Excerpt :

      As an alternative method to quantify turnover of low clearance drugs, the metabolite formation assay is used, with subsequent fitting to Michaelis–Menten equation or a substrate inhibition model (Pelkonen and Turpeinen, 2007). Further prediction of the in vivo metabolic clearance (CL) based on in vitro results (CLint measurement made in in vitro systems i.e., microsomes, hepatocytes or any other systems) requires many scaling factors and physiological measures such as liver weight, liver blood flow, extra-hepatic metabolism and clearances via other routes than hepatic metabolism (Barter et al., 2007; Brown et al., 2007; Emoto et al., 2010; Ong et al., 2013; Pelkonen et al., 2013). For reliable extrapolation of CLint to other tissue concentration, in vitro estimation of Km and Vmax and their subsequent use in PBBK model is needed (Bessems et al., 2014).

    • Exposure time versus cytotoxicity for anticancer agents

      2019, Cancer Chemotherapy and Pharmacology
    View all citing articles on Scopus
    1

    Permanent address: Department of Pesticides, Menoufia University, P.O.Box 32511, Egypt.

    View full text